UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~June 1518, 2025

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Delaware	001-36457	90-0031917
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

800 S. Gay Street, Suite 1610, Knoxville, Tennessee 37929

(Address of Principal Executive Offices) (Zip Code)

(866) 594-5999

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 47.01. ~~Changes~~Regulation inFD ~~Registrant’s Certifying Accountant~~Disclosure.

OnDuring ~~November~~its 1,annual ~~2024,~~meeting ~~CBIZ CPAs P.C. (“CBIZ”) acquired the attest business~~ of ~~Marcum~~stockholders ~~LLP~~to ~~(“Marcum”),~~be ~~and~~held ~~substantially all of the partners and staff that provided attestation services for Marcum joined CBIZ. Accordingly,~~ on ~~April~~June 1518, 2025, asProvectus ~~a result of the acquisition~~Biopharmaceuticals, ~~Marcum~~Inc. ~~resigned as~~ (the ~~independent registered public accounting firm of the~~ “Company”) ~~and,~~will ~~with~~provide an ~~the~~update ~~approval of~~about the Company’s ~~Audit~~clinical ~~Committee~~development, ofregulatory ~~the~~affairs, ~~Board~~drug ofdiscovery, ~~Directors~~manufacturing, ~~CBIZ~~intellectual ~~was~~property, ~~engaged as the Company’s independent registered public~~business ~~accounting~~development, ~~firm~~and oncorporate ~~the~~development ~~same date~~activities.

~~The~~A ~~audit~~copy ~~report~~ of ~~Marcum on~~ the Company’s ~~consolidated~~2025 ~~financial~~Annual ~~statements~~Meeting as of ~~and~~Stockholders ~~for~~presentation ~~the~~slides ~~fiscal~~is ~~years~~attached ~~ended~~to ~~December~~this ~~31,~~Current ~~2024 and~~Report ~~2023~~on ~~did~~Form ~~not~~8-K ~~contain~~as Exhibit an99.1 ~~adverse opinion or a disclaimer of opinion,~~ and ~~was~~is ~~not~~incorporated ~~qualified~~herein orby ~~modified as to uncertainty, audit scope, or accounting principles~~reference.

~~During~~Pursuant to the ~~fiscal~~rules ~~years~~and ~~ended~~regulations ~~December~~of ~~31,~~the ~~2024~~Securities and ~~December~~Exchange 31Commission, ~~2023, and through April 15, 2025,~~ the ~~date~~information ~~of Marcum’s resignation, there were (a) no “disagreements” (as defined~~ in this Item ~~304(a)(1)(iv)~~7.01 ~~of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement~~ disclosure, orincluding ~~auditing~~Exhibit 99.1 ~~scope~~and orinformation ~~procedures,~~set ~~which~~forth ~~disagreements~~therein, if ~~not~~is ~~resolved~~deemed to ~~the~~have ~~satisfaction~~been offurnished ~~Marcum,~~and ~~would~~shall ~~have~~not ~~caused~~be ~~Marcum~~deemed to ~~make~~be ~~reference to such disagreement in its report and (b) no~~ “~~reportable events~~filed” ~~(as~~under ~~defined~~the Securities inExchange ~~Item~~Act ~~304(a)(1)(v)~~ of ~~Regulation~~1934, ~~S-K)~~as amended.

During the fiscal years ended December 31, 2024 and December 31, 2023, and through April 15, 2025, neither the Company nor anyone on the Company’s behalf consulted with CBIZ regarding (i) the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ on the Company’s financial statements, and CBIZ did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing, or financial reporting issue or (ii) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S- K and the related instructions) or a “reportable event” (as defined in Item 304(a)(1)(v) of Regulation S-K).

The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (the “SEC”) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter, dated April 16, 2025, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
16.1		Letter from Marcum, dated April 16, 2025
99.1		2025 Annual Meeting of Stockholders presentation slides
104		Cover Page Interactive ~~Data~~Date File (the cover page XBRL tags are embedded within the ~~Inline~~inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~April~~June 1618, 2025

	PROVECTUS BIOPHARMACEUTICALS, INC.

	By:	/s/ Heather Raines
		Heather Raines
		Chief Financial Officer (Principal Financial Officer)

Filing Compare · PROVECTUS BIOPHARMACEUTICALS, INC.